Mathematical Model-Based Accelerated Development of Extended-release Metformin Hydrochloride Tablet Formulation
- PMID: 26729531
- DOI: 10.1208/s12249-015-0423-9
Mathematical Model-Based Accelerated Development of Extended-release Metformin Hydrochloride Tablet Formulation
Abstract
A computational fluid dynamic (CFD) model was developed to predict metformin release from a hydroxypropylmethylcellulose (HPMC) matrix-based extended-release formulation that took into consideration the physical and chemical properties of the drug substance, composition, as well as size and shape of the tablet. New high dose strength (1000 mg) tablet geometry was selected based on the surface area/volume (SA/V) approach advocated by Lapidus/Lordi/Reynold to obtain the desired equivalent metformin release kinetics. Maintaining a similar SA/V ratio across all extended-release metformin hydrochloride (Met XR) tablet strengths that had different geometries provided similar simulations of dissolution behavior. Experimental dissolution profiles of three lots of high-strength tablets agreed with the simulated release kinetics. Additionally, a pharmacokinetic absorption model was developed using GastroPlus™ software and known physicochemical, pharmacokinetic, and in vitro dissolution properties of metformin to predict the clinical exposure of the new high strength (1000 mg) tablet prior to conducting a human clinical bioequivalence study. In vitro metformin release kinetics were utilized in the absorption model to predict exposures in humans for new 1000-mg Met XR tablets, and the absorption model correctly projected equivalent in vivo exposure across all dose strengths. A clinical bioequivalence study was pursued based on the combined modeling results and demonstrated equivalent exposure as predicted by the simulations.
Keywords: CFD; GastroPlus; HPMC; diffusion; mathematical model; scale-up; surface area; volume.
Similar articles
-
[The use of natural and synthetic hydrophilic polymers in the formulation of metformin hydrochloride tablets with different profile release].Polim Med. 2012;42(3-4):167-84. Polim Med. 2012. PMID: 23457958 Polish.
-
Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.Mol Pharm. 2017 Jan 3;14(1):53-65. doi: 10.1021/acs.molpharmaceut.6b00677. Epub 2016 Dec 12. Mol Pharm. 2017. PMID: 27809538
-
Bilayer Tablet Formulation of Metformin HCl and Acarbose: A Novel Approach To Control Diabetes.PDA J Pharm Sci Technol. 2014 Mar-Apr;68(2):138-52. doi: 10.5731/pdajpst.2014.00953. PDA J Pharm Sci Technol. 2014. PMID: 24668601
-
Metformin extended release--DepoMed: metformin, metformin gastric retention, metformin GR.Drugs R D. 2004;5(4):231-3. doi: 10.2165/00126839-200405040-00009. Drugs R D. 2004. PMID: 15230631 Review.
-
Simulation of Unit Operations in Formulation Development of Tablets Using Computational Fluid Dynamics.AAPS PharmSciTech. 2020 Mar 12;21(3):103. doi: 10.1208/s12249-020-1635-1. AAPS PharmSciTech. 2020. PMID: 32166477 Review.
Cited by 3 articles
-
Bioequivalence and Safety Assessment of Two Formulations of Metformin Hydrochloride Sustained-Release Tablets (Yuantang® SR and Glucophage® XR) Under Fed Conditions in Healthy Chinese Adult Subjects: An Open-Label, Two-Way Crossover, Sequence Randomized Phase I Clinical Trial.Drugs R D. 2022 Mar;22(1):51-60. doi: 10.1007/s40268-021-00377-w. Epub 2022 Jan 21. Drugs R D. 2022. PMID: 35061235 Free PMC article. Clinical Trial.
-
Artificial intelligence in drug discovery and development.Drug Discov Today. 2021 Jan;26(1):80-93. doi: 10.1016/j.drudis.2020.10.010. Epub 2020 Oct 21. Drug Discov Today. 2021. PMID: 33099022 Free PMC article. Review.
-
Computational Approaches in Preclinical Studies on Drug Discovery and Development.Front Chem. 2020 Sep 11;8:726. doi: 10.3389/fchem.2020.00726. eCollection 2020. Front Chem. 2020. PMID: 33062633 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous